Form 4: Director Muneer Satter Increases Annexon Stake

Director Muneer A. Satter acquired 613,497 shares of Annexon, Inc. common stock at a price of $5.41 per share.

Summary

• Director Muneer A. Satter purchased 613,497 shares of Annexon, Inc. (ANNX) common stock on May 28, 2026.
• The shares were acquired at a price of $5.41 per share.
• The purchase was executed through Alerce Medical Technology Partners, L.P., an entity over which the director holds sole voting and dispositive power.
• Following this transaction, the reporting person's total beneficial ownership increased to 10,342,134 shares.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, as significant open-market purchases by a director demonstrate alignment with shareholder interests and confidence in the company's valuation.

Positives

• Significant insider accumulation of 613,497 shares indicates strong confidence from a director in the company's long-term prospects.
• The purchase price of $5.41 reflects a substantial capital commitment by the director.

Negatives

• None identified in this filing.

Risks

• The reporting person disclaims beneficial ownership of the majority of the shares held, except to the extent of his pecuniary interest, which may complicate the interpretation of total economic exposure.

Future Outlook

Not applicable as this is a disclosure of a past transaction.

Industry Context

StockSavvy.ai notes that insider buying in the biotechnology sector is often viewed as a positive signal, particularly when directors increase their positions during periods of market volatility or ahead of clinical milestones.

Comparison to Industry Standards

• Insider buying of this magnitude is generally considered a strong bullish signal compared to standard executive compensation-based equity grants.
• The transaction aligns with typical behavior for long-term institutional investors or directors who maintain significant stakes in clinical-stage biotech firms.

Related Party Transactions

• The shares were purchased by Alerce Medical Technology Partners, L.P., an entity controlled by the reporting person.

Stakeholder Impact

• Shareholders may perceive this as a vote of confidence in the company's current strategic direction and valuation.

Key Dates

Keywords

Annexon, ANNX, Insider Trading, Form 4, Muneer Satter, Biotech, Equity Acquisition